# Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

> **NCT07317115** · NA · RECRUITING · sponsor: **GT Metabolic Solutions, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Obesity (Disorder)
- Obesity & Overweight
- Type 2 Diabetes (T2DM)

## Interventions

- **DEVICE:** Magnet System
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT07317115
- **Lead sponsor:** GT Metabolic Solutions, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07317115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07317115, "Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07317115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*